Resources from the same session
1451MO - In-situ immune markers predict nivolumab (N) +/-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized trial
Presenter: Maxime Meylan
Session: Mini Oral session 2: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
1452MO - Longitudinal analysis reveals gut microbiota shift during standard therapies in metastatic renal cell carcinoma (mRCC)
Presenter: Carolina Alves Costa Silva
Session: Mini Oral session 2: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
LBA69 - Belzutifan, a HIF-2α Inhibitor, for von Hippel-Lindau (VHL) disease-associated neoplasms: 36 months of follow-up of the phase II LITESPARK-004 study
Presenter: Ramaprasad Srinivasan
Session: Mini Oral session 2: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
1736MO - Pure or mixed basal/squamous tumours present decreased outcomes after neoadjuvant chemotherapy in the GETUG-AFU V05 VESPER trial
Presenter: Clarice Groeneveld
Session: Mini Oral session 2: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
1737MO - Tumor and immune features associated with disease-free survival with adjuvant nivolumab in the phase III CheckMate 274 trial
Presenter: Andrea Necchi
Session: Mini Oral session 2: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant 1736MO and 1737MO
Presenter: Michiel van der Heijden
Session: Mini Oral session 2: GU tumours, non-prostate
Resources:
Slides
Webcast